NDAORALTABLET
Approved
Feb 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ALTACE (ramipril) by Pfizer is animals. First approved in 2007.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTACE (ramipril) is an oral ACE inhibitor tablet approved for hypertension management that works by inhibiting angiotensin-converting enzyme, reducing angiotensin II formation and decreasing vasopressor activity. It lowers blood pressure through suppression of the renin-angiotensin-aldosterone system and demonstrates efficacy across racial populations, including low-renin hypertensive patients.
$0.002BPart D
LOE ApproachingWith LOE approaching and modest Part D spending ($2M, 2732 claims in 2023), the brand team is likely consolidating rather than expanding, signaling career focus on managed decline and generic transition strategies.
Mechanism of Action
animals. Angiotensin converting enzyme is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II,…
Indications
Worked on ALTACE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.